$RLAY insider trading
Over the last 12 months, Relay Therapeutics insiders reported no purchases and 29 sales totaling $128.8M across SEC Form 4 filings. 48% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $128.8M 29 events
- Events · 12m
- 29 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 48% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Patel SanjivPresident and CEO · O·D | ▼ Sale | 48,199 | $18.94 | $913K | -8.5% | plan |
| Sep 8, 2026 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 8,530 | $18.97 | $162K | -2.1% | plan |
| Sep 8, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 17,717 | $18.94 | $336K | -12.6% | plan |
| Aug 26, 2026 | Rahmer PeterSee remarks · O | ▼ Sale | 4,508 | $20.03 | $90K | -2% | plan |
| Aug 25, 2026 | SVF Pauling (Cayman) Ltd10% | ▼ Sale | 6,000,000 | $19.4 | $116.4M | -21.5% | indirect |
| Aug 17, 2026 | Patel SanjivPresident and CEO · O·D | ▼ Sale | 48,199 | $20.33 | $980K | -7.8% | plan |
| Aug 14, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 17,717 | $19.74 | $350K | -11.2% | plan |
| Jul 28, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 1,459 | $18.61 | $27K | -0.9% | — |
| Jul 28, 2026 | Rahmer PeterSee remarks · O | ▼ Sale | 748 | $18.61 | $14K | -0.3% | — |
| Jul 28, 2026 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 2,237 | $18.61 | $42K | -0.5% | — |
| Jul 7, 2026 | Patel SanjivPresident and CEO · O·D | ▼ Sale | 48,199 | $19.58 | $944K | -7.3% | plan |
| Jul 6, 2026 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 8,660 | $18.71 | $162K | -2.1% | plan |
| Jul 6, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 17,717 | $18.69 | $331K | -10% | plan |
| Jun 30, 2026 | Rahmer PeterSee remarks · O | ▼ Sale | 50,000 | $19.09 | $955K | -18.1% | plan |
| Jun 22, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 187,163 | $16.97 | $3.2M | -51.3% | plan · 4 tranches |
| Jun 22, 2026 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 93,456 | $16.94 | $1.6M | -18.3% | plan |
| Apr 28, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 972 | $14.79 | $14K | -0.5% | — |
| Apr 28, 2026 | Rahmer PeterSee remarks · O | ▼ Sale | 753 | $14.79 | $11K | -0.3% | — |
| Apr 28, 2026 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 1,490 | $14.79 | $22K | -0.4% | — |
| Apr 9, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 19,517 | $13.19 | $257K | -8.4% | plan · 2 tranches |
| Mar 9, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 17,717 | $10.06 | $178K | -7.1% | plan |
| Jan 28, 2026 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 21,581 | $7.72 | $167K | -4.9% | 2 tranches |
| Jan 28, 2026 | Rahmer PeterSee remarks · O | ▼ Sale | 13,038 | $7.71 | $100K | -4.5% | 2 tranches |
| Jan 28, 2026 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 15,515 | $7.71 | $120K | -5.9% | 2 tranches |
| Jan 6, 2026 | Patel SanjivPresident and CEO · O·D | ▼ Sale | 43,168 | $7.82 | $338K | -6.1% | — |
| Nov 3, 2025 | Patel SanjivPresident and CEO · O·D | ▼ Sale | 62,073 | $7 | $435K | -8.1% | — |
| Oct 29, 2025 | Rahmer PeterSee remarks · O | ▼ Sale | 40,529 | $7.4 | $300K | -10.7% | 2 tranches |
| Oct 28, 2025 | Catinazzo ThomasChief Financial Officer · O | ▼ Sale | 21,664 | $7.29 | $158K | -6.5% | — |
| Oct 28, 2025 | Bergstrom Donald APresident, R&D · O | ▼ Sale | 30,897 | $7.29 | $225K | -5.6% | — |
Every $RLAY filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Relay Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RLAY feed.